- Rosiglitazone HCl
-
- $1.00 / 1KG
-
2024-04-22
- CAS:302543-62-0
- Min. Order: 1KG
- Purity: 99.91%
- Supply Ability: 200000
|
| | Rosiglitazone hydrochloride Basic information |
| Product Name: | Rosiglitazone hydrochloride | | Synonyms: | ROSIGLITAZONE HYDROCHLORIDE 99%;5-[4-[2-[N-Methyl-N- (pyridinyl) amino]ethoxy]benzyl]thiazolidine-2,4-dione hydrochloride;Rosiglitazone hydrochloride;Rosiglitazone hydroc;5-(4-(2-(Methyl(pyridin-2-yl)aMino)ethoxy)benzyl)thiazolidine-2,4-dione hydrochloride;5-[(4-{2-[Methyl(pyridin-2-yl)aMino]ethoxy}phenyl)Methyl]-1,3-thiazolidine-2,4-dione hydrochloride;5-[[4-[2-(methyl-2-pyridinylamino)ethoxy]phenyl]methyl]-2,4-thiazolidinedione, hydrochloride (1:1);BRL-49653 HCl | | CAS: | 302543-62-0 | | MF: | C18H20ClN3O3S | | MW: | 393.89 | | EINECS: | 1308068-626-2 | | Product Categories: | Inhibitors;API;Inhibitor | | Mol File: | 302543-62-0.mol |  |
| | Rosiglitazone hydrochloride Chemical Properties |
| storage temp. | Store at -20°C | | solubility | ≥39.4 mg/mL in DMSO; ≥2.81 mg/mL in H2O with gentle warming and ultrasonic; ≥51.2 mg/mL in EtOH with ultrasonic | | form | solid | | color | White to off-white | | InChI | InChI=1S/C18H19N3O3S.ClH/c1-21(16-4-2-3-9-19-16)10-11-24-14-7-5-13(6-8-14)12-15-17(22)20-18(23)25-15;/h2-9,15H,10-12H2,1H3,(H,20,22,23);1H | | InChIKey | XRSCTTPDKURIIJ-UHFFFAOYSA-N | | SMILES | C(C1C=CC(OCCN(C2N=CC=CC=2)C)=CC=1)C1C(NC(=O)S1)=O.Cl | | CAS DataBase Reference | 302543-62-0(CAS DataBase Reference) |
| | Rosiglitazone hydrochloride Usage And Synthesis |
| Chemical Properties | Rosiglitazone is a hypoglycemic drug developed by GS, and the revalent compounds are disclosed in European Patent EP 306228. | | Uses | Rosiglitazone hydrochloride has better stability than rosiglitazone maleate, and is very suitable for application in the manufacture of common pharmaceutical preparations. It is a thiazolidinedione antidiabetic drug, which can effectively control blood sugar by improving insulin sensitivity. | | Biological Activity | rosiglitazone is a blood glucose-lowering drugs, stimulating insulin secretion by binding to the ppar receptors in fat cells. | | in vivo | Rosiglitazone hydrochloride (oral administration, 5 mg/kg, daily for 8 weeks) decreases the serum glucose in diabetic rats[5].
Rosiglitazone hydrochloride (intraperitoneal injection, 3 mg/kg/day) ameliorates airway inflammation induced by cigarette smoke via inhibiting the M1 macrophage polarization by activating PPARγ and RXRα in male Wistar rats[6].
Rosiglitazone hydrochloride (intraperitoneal injection, 10 mg/kg, once every 2 days) inhibits subcutaneous ovarian cancer growth in A2780 and SKOV3 mouse subcutaneous xenograft models[7]. | Animal Model: | Streptozotocin (STZ)-induced diabetic rats[5] | | Dosage: | 5 mg/kg | | Administration: | Oral administration, daily for 8 weeks. | | Result: | Decreased IL-6, TNF-α, and VCAM-1 levels in diabetic group.
Displayed lower levels of lipid peroxidation and NOx with an increase in aortic GSH and SOD levels compared to diabetic groups.
|
| Animal Model: | Male Wistar rats[6] | | Dosage: | 3 mg/kg/day | | Administration: | Intraperitoneal injection, twice a day, 6 days per week for 12 consecutive weeks | | Result: | Ameliorated emphysema, elevated PEF, and higher level of total cells, neutrophils and cytokines (TNF-α and IL-1β) induced by cigarette smoke (CS).
Inhibited CS-induced M1 macrophage polarization and decreased the ratio of M1/M2.
|
| | target | | | IC 50 | PPARγ: 40 nM (Kd); PPARγ: 60 nM (EC50); TRPC5: 30 μM (EC50); TRPM3 |
| | Rosiglitazone hydrochloride Preparation Products And Raw materials |
|